David Novak

Stock Analyst at Raymond James

(1.11)
# 3,803
Out of 5,044 analysts
9
Total ratings
44.44%
Success rate
-9.31%
Average return
Main Sectors:
Top Industries:

Stocks Rated by David Novak

Zymeworks
Dec 10, 2021
Downgrades: Outperform
Price Target: $74
Current: $19.38
Upside: +281.84%
Leap Therapeutics
Mar 2, 2021
Maintains: Outperform
Price Target: $25$35
Current: $0.48
Upside: +7,220.64%
Crescent Biopharma
Feb 4, 2021
Maintains: Outperform
Price Target: $300$270
Current: $12.50
Upside: +2,060.00%